We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Essity Ab (publ) | LSE:0RQC | London | Ordinary Share | SE0009922156 | ESSITY ORD SHS CLASS A |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 224.75 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 173.92B | 9.55B | 13.6030 | 1.94 | 157.85B |
From Dec 2023 to Dec 2024
STOCKHOLM, Dec. 14, 2023 /PRNewswire/ -- The Consumer Tissue Private Label Europe business remains a part of the Essity Group and thereby the strategic review of the division, which began on April 26 of this year, is concluded.
Essity continuously evaluates its various businesses to increase long-term value creation. In the strategic review of Consumer Tissue Private Label Europe it was concluded that the business as a result of the implemented divisionalization, is a competitive and value-creating part of Essity.
Net sales for the Consumer Tissue Private Label Europe business amounted to approximately SEK 9.8bn in 2022. The business encompasses seven production facilities in Belgium, France, Germany and Italy with approximately 1,900 employees.
NB: This is information that Essity Aktiebolag (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 17:30 CET on December 14, 2023.
Karl Stoltz, Media Relations Director, +46 709 42 63 38
CONTACT:
For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55, per.lorentz@essity.com
Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89, sandra.aberg@essity.com
The following files are available for download:
https://mb.cision.com/Main/15798/3891772/2494179.pdf | Strategic review of the Consumer Tissue Private Label Europe business concluded |
View original content:https://www.prnewswire.com/news-releases/strategic-review-of-the-consumer-tissue-private-label-europe-business-concluded-302015872.html
SOURCE Essity
Copyright 2023 PR Newswire
1 Year Essity Ab (publ) Chart |
1 Month Essity Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
